Atossa Genetics to Present at OneMedForum and Biotech Showcase

SEATTLE, WA--(Marketwire - Jan 3, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that Dr. Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President, will present at the OneMedForum at the Sir Francis Drake Hotel in San Francisco, on Tuesday, January 8, 2013, at 4:00 pm Pacific Time (7:00 pm Eastern Time) and at the Biotech Showcase at the Parc 55 Wyndham Hotel in San Francisco on Wednesday, January 9, 2013, at 10:00 am Pacific Time (1:00 pm Eastern Time). Dr. Quay's presentations will be webcast via the Company's website at www.atossagenetics.com.

Dr. Quay stated, "I look forward to presenting our business model, breast health products and services to institutional investors at these prestigious events. I believe the U.S. roll out of our ForeCYTE Breast Health Test and ArgusCYTE Breast Health Test, launch of two additional tests, FullCYTE Breast Health Test and NextCYTE Breast Health Test, and initiation of clinical trials for our intraductal therapy offer investors a compelling investment thesis for 2013 and beyond."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Atossa's plans, expectations, projections, potential opportunities, goals and objectives are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services and other risks detailed from time to time in the Atossa's final prospectus, dated November 7, 2012, filed with the U.S. Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Atossa undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.